Username:
  
  Password:
  
  

Exhibit 10.1

 

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and Rule 406 of the Securities Act if 1933, as amended.

 

FIRST AMENDMENT
TO THE
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT

 

THIS FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “First Amendment” ) is made by and between SENOMYX, INC. ( “Senomyx” ), a Delaware corporation, having a principal place of business at 4767 Nexus Centre Drive, San Diego, CA 92121, and NESTEC, Ltd. ( “Nestlé” ), a Swiss company, having a principal place of business at Avenue Nestlé 55, CH-1800 Vevey, Switzerland.

 

WHEREAS, Senomyx and Nestlé entered into that certain Collaborative Research and License Agreement dated as of October 26, 2004 (the “Agreement” ); and

 

WHEREAS, the parties wish to amend the Agreement in the manner set forth in this First Amendment (capitalized terms used but not otherwise defined in this First Amendment shall have the meanings given such terms in the Agreement).

 

NOW, THEREFORE, in consideration of the foregoing premises and of the covenants, representations and agreements set forth below, the parties hereby agree to amend the Agreement as follows:

 

AGREEMENT

 

1.                                         Appendix A to the Agreement is hereby amended by either adding or amending, as provided below, the following definitions:

 

[…***…] means […***…] is not included. Leading brands in […***…] include […***…].  Notwithstanding the foregoing, the […***…] category specifically excludes all products that contain […***…].

 

[…***…] Products ” means […***…].  For the avoidance of doubt, […***…] Products excludes […***…].

 

Collaborative Period ” means the period beginning on the Effective Date and ending July 25, 2010, unless earlier terminated in accordance with Section 14 or extended by the Steering Committee in accordance with Section 7.1.

 

Discovery Phase ” means the portion of the Collaborative Period commencing on July 26, 2008 and ending January 25, 2009.

 

***Confidential Treatment Requested

 



 

“Development Phase” means the portion of the Collaborative Period commencing on January 26, 2009 and ending July 25, 2010.  The Development Phase may be extended by the Steering Committee in accordance with Section 7.1.

 

First Amendment Effective Date ” means May 1, 2009.

 

[…***…] means […***…].  Notwithstanding the foregoing, the […***…] category specifically excludes all products that contain added […***…].

 

Research Phase ” means the portion of the Collaborative Period commencing on the Effective Date and ending […***…].

 

Safety Studies ” means the following safety studies that Senomyx anticipates would be needed to complete a […***…] submission:  […***…].

 

[…***…] means […***…]. Notwithstanding the foregoing, the […***…]category specifically excludes all products that contain […***…].

 

2.                                         Section 7.1 of the Agreement is hereby amended and restated in its entirety as follows:

“7.1
                      Research Funding. During the Collaborative Period, Nestlé will provide funding to Senomyx for the Collaborative Program according to the following schedule:

 

(A)                             USD […***…] per quarter during the Research Phase;

 

(B)                               USD […***…] per quarter during the Discovery Phase; and

 

(C)                               USD […***…] per quarter during the Development Phase.

 

If there are unanticipated delays and the Steering Committee determines that it is necessary for the


This is only a partial view of this document. We have millions of legal documents and clauses drafted by top law firms. learn more search for free browse for free learn more